New financing is available every day.

500 million yuan, 200 million yuan, 100 million yuan…

Recently in Jiangbei District, the “popularity” has been on the rise. Eight enterprises have successively announced good news about their financing. From gene-editing drugs to millimeter-wave radars, from innovative anti-cancer drugs to semiconductor materials, enterprises in different sectors and at different stages have all received a large number of “trust votes” from capital.

“New financing is happening every day.” This once somewhat exaggerated statement is gradually becoming the real daily routine in this thriving region.

If we sort out these 8 financing transactions one by one, we can clearly see a clear chain of innovation.

At the end of May, Ji Moxin and Yuanmai Cell were the first to secure financing. Ji Moxin focuses on two-dimensional semiconductor materials and has completed an angel round of financing; Yuanmai Cell mainly works on CAR-M and has also received support in the Pre-A round this time.

Yao Tang Biotech followed closely behind. With a C-round financing of nearly 500 million yuan, it was led by Zhengxin Valley Capital, with participation from Shanghai Guotu Lianxian, old shareholders Shuangfeng Qi Yun, and others. The lineup was complete. This enterprise developing in vivo gene editing drugs is demonstrating a strong “financing ability”.

As June arrived, good news came in an even more frequent stream:

On June 1st, Jin Ran Biotechnology announced the completion of its Pre-A round of financing. This biotechnology manufacturing enterprise plans to use the funds from this round of financing to focus on the technological iteration of new biodegradable chiral materials, expansion of production capacity, and expansion of market channels, in order to accelerate the industrialization process.
On June 2nd, Weikel Medicine and Xuanjia Technology successively announced the completion of their latest rounds of financing. One was a C3 round of financing totaling nearly 200 million yuan, with the Pre-IPO financing process underway; the other was the first phase of the B round financing, both of which are crucial boosts for the companies as they strive for the next stage of development.
On June 3rd, Chuhang Technology announced the completion of its C-round financing, with the total amount exceeding 100 million yuan. As a “key player” in multi-modal millimeter-wave radar technology, the team will continue to expand the company’s leading position in the field of spatial intelligent perception.
On June 4th, Xiu Yi Technology announced the completion of a new round of financing. This young enterprise, which was established only three years ago, is emerging as a pioneering force in the field of membrane separation technology…

From its early start to the rush to go public, from biomedicine to advanced materials, one after another, deal after deal, the innovative vitality of the new zone has thus emerged.

Eight enterprises conducted concentrated fundraising and attracted significant attention from investors because each of them had its own “winning strategies”.

The largest amount of this round of financing came from Ya Tang Biotechnology. This innovative team has already had 6 research lines enter the clinical stage, leading the world. The first domestically developed in vivo gene editing drug based on LNP, which is entering the registration clinical trial, originated from this team.

The small molecule targeted anti-tumor new drug Anrituximab (VC004), independently developed by Weikel Medicine, has been approved for market release. The Vicaagrel Capsule has been selected four times for the national science and technology major projects. The MACF-001 project of Yuanmai Cell completed the first patient enrollment and concluded the safety follow-up at the Liver Disease Center of the Eastern Theater Command General Hospital. The patient’s indicators related to liver cirrhosis showed significant improvement.

Chuhang Technology’s millimeter-wave radar has entered the supply chains of 30 automotive manufacturers including Geely, Chery, and Great Wall. The team has also deeply participated in the formulation of industry standards. The products of Jimei Molybdenum Core serve top research institutions and industrial organizations such as Cambridge University, the Chinese University of Hong Kong, and Fudan University, and have already reached cooperation with downstream chip manufacturers…

Not only do we have “winning strategies”, but this strategy has actually been implemented, worked out, and has been verified by the market. With sufficient capabilities, we naturally win the favor of capital.

A wave of “financing enthusiasm” is good news for eight enterprises; looking deeper, we can also see a vibrant industrial ecosystem.

Take Yuanmai Cell and Jiemu Core as examples. Both are enterprises from the “Nanjing University” group. The founder of Jiemu Core, Dr. Zhuo Fulin, graduated from Nanjing University and started the business with his colleagues. The founder of Yuanmai Cell, Shen Pingping, is a professor at the School of Life Sciences of Nanjing University and has been deeply involved in this field for over 20 years.

This is no coincidence. In Jiangbei, there are always university research achievements taking root and flourishing here. Universities like Nanjing University, Dongnan University, and Pharmaceutical University have closely collaborated with the new district. Professors lead their students in starting businesses, senior students bring junior students into the venture, and excellent technologies are directly transformed here, which has become a common practice.

Let’s look at the industrial support. Among the 8 newly-funded enterprises, half are located in the Biomedical Valley. In this park, there are over 1,300 enterprises clustered together. Perhaps by taking a few steps, one can find upstream and downstream partners and access clinical resources. The time for new ideas to turn into new products has been significantly shortened, and thus the enterprises can operate more efficiently.

A number of enterprises have been receiving good news in a concentrated manner because there has long been a lush “science and technology innovation forest” in Jiangbei. This is the real foundation for “having new financing every day”, and it is also the natural outcome achieved by Jiangbei through long-termism.

The story continues.
Looking forward to more good news!